Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2023.7119Source: DataRank Database

Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events is a research paper published in Journal of the National Comprehensive Cancer Network (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.36)OA: bronzeTopics (28)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Nicolas L. Palaskas ORCID,Bilal A. Siddiqui ORCID,Jennifer L. McQuade ORCID,Jamie S. Lin ORCID,Sumit K. Subudhi ORCID

Live enrichment

PubMed:38190801 PMC:PMC12381944 OpenAlex:https://openalex.org/W4390674497

NCI NIH HHS

Grant: P01 CA261669

NIDDK NIH HHS

Grant: K08 DK119466

NCI NIH HHS

Grant: P30 CA016672

FWCI

0.36

Citation Percentile

0.6%

Citation Trend

2024

2025

bronze

journalhttps://jnccn.org/downloadpdf/view/journals/jnccn/aop/article-10.6004-jnccn.2023.7119/article-10.6004-jnccn.2023.7119.pdf

publisherhttps://jnccn.org/downloadpdf/view/journals/jnccn/aop/article-10.6004-jnccn.2023.7119/article-10.6004-jnccn.2023.7119.pdf

publisherhttps://jnccn.org/view/journals/jnccn/22/5/article-e237119.xml

publisherhttps://jnccn.org/downloadpdf/journals/jnccn/22/5/article-e237119.xml

journalhttps://doi.org/10.6004/jnccn.2023.7119

Fields of Study

Cancer Immunotherapy and BiomarkersEconomic and Financial Impacts of CancerPancreatic and Hepatic Oncology ResearchHumansNeoplasmsImmune Checkpoint InhibitorsDrug-Related Side Effects and Adverse ReactionsTexasImmunotherapy

MeSH Terms

Immune Checkpoint InhibitorsHumansImmunotherapyNeoplasmsTexasDrug-Related Side Effects and Adverse Reactions

Keywords

MedicineAdverse effectBest practiceCancerClinical PracticeOncologyCancer treatmentImmune systemIntensive care medicineClinical trialFamily medicineInternal medicineImmunology